Cathepsin D, Fluorometric 390, BioAssay™ Kit (CatD, CLN10, CPSD, CTSD, Lysosomal aspartyl peptidase, MGC2311)

Referência C2097-33-1Kit

Tamanho : 1Kit

Marca : US Biological

Solicitar mais informações

Contactar o distribuidor local :


Telefone : +1 850 650 7790


C2097-33 Cathepsin D, Fluorometric 390, BioAssay™ Kit (CatD, CLN10, CPSD, CTSD, Lysosomal aspartyl peptidase, MGC2311) discontinued

Clone Type
Polyclonal
Applications
E
Shipping Temp
BI/DI
Storage Temp
-20°C/-70°C

This kit is optimized to detect Cathepsin D activity. Enhanced Value: It provides enough reagents to perform 100 assays in a 96-well format. ||High Speed: The entire process can be completed in one hour||Cathepsin D is the lysosomal aspartic proteinase implicated in intracellular protein degradation. It is involved in several pathological processes, such as inflammatory states, atherosclerosis, thrombosis, apoptosis, neoplastic proliferation or Alzheimer disease. |This kit provides a convenient assay for screening of enzyme inhibitors and for continuous assay of Cathepsin D activity using a Mca/Dnp FRET peptide. The sequence of this FRET peptide is derived from the cleavage site of Cathepsin D. In the FRET peptide, the fluorescence of Mca is quenched by Dnp. Upon cleavage into two separate fragments by Cathepsin D, the fluorescence of Mca is recovered, and can be monitored at excitation/emission = 330nm/390nm.|||Kit Components:|C2097-33A: Cathepsin D substrate (1.6mM), Ex/Em=330nm / 390nm upon cleavage, 1x50ul|C2097-33B: Standard (2mM,), Ex/Em=330nm/390nm, 1x10ul|*C2097-33C: Cathepsin D, bovine spleen (0.1mg/ml), 1x20 ul|C2097-33D: Assay Buffer, 20ml|C2097-33E: Pepstatin A (4mM), 1x100ul|C2097-33F: DTT (1M), 1x100ul||Storage and Stability:|Store *C2097-33C at -70°C. Store other components at 20°C. Stable for 6 months For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Applications
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
References
1. Berchem, G. et al, Oncogene 21, 5951(2002). 2. Liaudet-Coopman, E. et al, Cancer Lett. 237, 167 (2006). 3. Davidson, Y. et al, J. Neurol. Neurosurg Psychiat. 77, 515 (2006). 4. Laurent-Matha, V. et al, J. Cell Biol. 168, 489 (2005). 5. Simon, DI. et al, Biochemistry 33, 6555 (1994). 6. Baechle, D. et al, J. Peptide Sci. 11, 166 (2005). 7. Yasuda, Y. et al, J. Biochem. 125, 1137 (1999).